Frontline therapy of multiple myeloma

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• The last decade has seen major advances in multiple myeloma treatment.
• Novel agents (thalidomide, bortezomib, lenalidomide) are now standard in frontline therapy.
• These agents improve remission rates and survival metrics.

Purpose of the Study:

• To review recent frontline therapeutic approaches for multiple myeloma.
• Focus on older patients ineligible for autologous stem cell transplantation (ASCT).
• Focus on younger patients eligible for early ASCT.

Main Methods:

• Review of recent clinical studies and therapeutic strategies.
• Analysis of frontline treatment regimens.
• Consideration of patient eligibility for ASCT.

Main Results:

• Novel agents have markedly improved complete remission rates.
• Significant increases observed in time to progression, progression-free survival, and overall survival.
• Recent approaches tailor therapy based on age and ASCT eligibility.

Conclusions:

• Frontline therapy with novel agents has transformed multiple myeloma management.
• Continued research is essential for optimizing treatment in diverse patient groups.
• Personalized therapeutic strategies are key for improving long-term outcomes.